CU6
data caveat$1.1B27mo
Clarity Pharmaceuticals
Biotech · Radiopharmaceuticals
Copper-based radiopharmaceuticals for cancer imaging and therapy, SAR-bisPSMA lead program
Data HealthTrials4 of 4 active · stale enrollment
Cash data from Dec 2025 4CFigures from ASX filings · not financial advice
[ VITALS ]
Cash on Hand
$226.3M
Dec 2025 4C
Runway
27moSTABLE
Based on Dec 2025 4C
Market Cap
$1.1B
Burn Rate
$25.1M/qtr
Dec 2025 4C
Shares Outstanding
372M
Pipeline Assets
3
Latest Insight(1)
10 Apr 2026substantial_holderCeasing to be a substantial holder
Ceased·Citigroup Global Markets Australia Pty Limited
3M Price
CU6.ASX$2.930-10.9% 3M
Low $2.730High $3.960
Pipeline Assets (3)
SAR-bisNTR1Pancreatic cancer imaging
Phase 1SAR-bisPSMA (therapy)Metastatic prostate cancer therapy
Phase 2SAR-bisPSMAMetastatic prostate cancer imaging
Phase 3Discovery
Preclinical
Ph 1
Ph 1/2
Ph 2
Ph 2/3
Ph 3
Capital Raises & Buybacks
2 raises
Current shares outstanding: 372M
Options
2026-03-31options exercise
0
2026-03-11options exercise
Substantial Holders (5%+ threshold)
4 noticesCEASEDCitigroup Global Markets Australia Pty Limited
INITIALCitigroup Global Markets Australia Pty Limited and related bodies corporate in the Citigroup group of companies worldwide
5.03%2026-04-09
INITIALThe Vanguard Group, Inc. and its controlled entities
5.01%
Director Options & Rights
Director
Outstanding
Ex. Price
Expiry
No option data entered yet
Short Interest
ASIC ↗as of 2026-03-27 · 4-day lag
Short position
8.25%
arrow_drop_up+0.38% over 30 reports
Shares short
30.7M
Aggregated short position data published by ASIC under the Corporations Act. T+4 reporting lag applies. Short interest ≥5% is noteworthy; ≥10% is elevated. Source: ASIC Short Selling Data
R&D Tax Incentive
$11.1M received43.5% ATO refund
FY2025received
Auto-extracted from 4C (2025-06-30)
$11.15M
How the R&D Tax Incentive works
Australian biotechs with < $20M aggregated turnover can claim a 43.5% refundable tax offseton eligible R&D expenditure each financial year (Jul–Jun). This is paid as a cash refund by the ATO — not a tax deduction — making it non-dilutive capital that directly extends cash runway.
Companies register eligible R&D activities with AusIndustry during the year, then lodge their tax return after 30 June. Refunds typically arrive October–Decemberof the same calendar year. For a company spending $5M/year on R&D, this is a ~$2.2M annual cash inflow.
Disclaimer: Amounts shown as estimated or registeredare forward-looking estimates based on disclosed R&D expenditure and the 43.5% offset rate. Actual refunds may differ due to ATO assessments, eligibility rulings, or changes in R&D spend. This is not financial advice. Manually curated from 4C filings and company disclosures — verify independently.
Competitive Landscape
229 competitor trialsPhase 2+ · Non-ASX
Pancreatic Cancer Imaging15 active trials
1 Ph42 Ph33 Ph2/34 Ph25 Ph1/PHASE2
Metastatic Prostate Cancer Therapy202 active trials
8 Ph448 Ph36 Ph2/3104 Ph236 Ph1/PHASE2
Metastatic Prostate Cancer Imaging12 active trials
3 Ph31 Ph2/37 Ph21 Ph1/PHASE2
Competitor trials from ClinicalTrials.gov (Phase 2+ historical, Phase 3+ refreshed weekly, active/recruiting, non-ASX sponsors). Approved drugs from OpenFDA (NDA/BLA only). Updated weekly via fetch_competitors.py.
expand_moreClinical Publications
Peer-reviewed papers & conference abstracts via PubMed
15 papers
Clinical Publications
Peer-reviewed papers & conference abstracts via PubMed
Hepatol Commun2026-05· therapy
Adv Skin Wound Care2026-05· therapy
Adv Skin Wound Care2026-05· therapy
Proc Natl Acad Sci U S A2026-04· therapy
Catalysts (9)· 4 upcoming · 5 past
CLARIFY trial enrolment close
UpcomingExpectedarrow_upwardHigh30 June 2026
SARTATE Phase 3 NETs trial start
UpcomingConfirmedremoveMed30 June 2026
AMPLIFY Phase 3 topline data
UpcomingExpectedarrow_upwardHigh30 Sept 2026
SECuRE Phase I/IIa continued enrolment
UpcomingExpected
Delivery Consistency Index
Historical delivery and spending consistency — data is limited for recently added companies.
Delivery Consistency Index
Delivery
–Insufficient data
0/3 data points needed
Timeline adherence · phase-adjusted tolerance · recency-weighted · min 3 catalysts
Capital discipline
High89/100
Burn rate stability · stage-adjusted thresholds · runway trend · R&D focus
What drove these scores · rolling 2yr
arrow_drop_down
1 burn spike — Quarter-on-quarter spend increase >50%
arrow_drop_up
Burn reductions achieved — 1 quarter with >30% spend reduction
arrow_drop_up
Cash position improving — Cash balance grew over last 3 quarters
arrow_drop_up
R&D-focused spend — 91% of opex directed to R&D
·
Phase 3+ thresholds — Burn rate variability thresholds adjusted for late-stage development
Outcome quality (positive/negative readouts) reflects the science, not execution — shown above but excluded from the score.
These metrics reflect historical operational data only. They are not predictive of future performance, do not constitute investment advice, and should not be used as the basis for any investment decision.
⚠ TIMELINE CHANGESCT.GOV · AUTO-DETECTED
These changes were automatically detected by comparing ClinicalTrials.gov records over time. A slipped date means the trial's expected completion moved later; pulled forward means it moved earlier.
Clinical Trials(11)
4 activeClinicalTrials.gov ↗
Ph1/PHASE2RecruitingEnrollment stale · 1715d
64Cu-SAR-bisPSMA67Cu-SAR-bisPSMA
64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE)
Prostatic Neoplasms, Castration-Resistant
18 Years+
Primary endpoint Biodistribution of 64Cu-SAR-bisPSMA
Ph2RecruitingEnrollment stale · 517d
64Cu-SAR-bisPSMA
Comparative Performance of 64Copper [64Cu]-SAR-bis-PSMA vs 68Ga PSMA-11 PET CT for the Detection of Prostate Cancer Recurrence in the Setting of Biochemical Failure Following Radical Prostatectomy
Prostate Cancer (Post Prostatectomy)
18 Years+
Primary endpoint Detection rate of lesions per participants, between 64Cu-SAR-bisPSMA and 68Ga PSMA-11 PET/CT
Ph3RecruitingEnrollment stale · 853d
64Cu-SAR-bisPSMA
Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy
Prostate Cancer · Prostatic Neoplasms
18 Years+
Primary endpoint Diagnostic performance of 64Cu-SAR-bisPSMA PET to detect regional nodal metastases